Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. - Wikidata - awgldk - TriplyDB

Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients.

Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients.

http://www.wikidata.org/entity/Q36583383

about

Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?Hyperphosphatemia. The hidden killer in chronic kidney disease Phosphate binders in chronic kidney disease: a systematic review of recent data.Lipid, blood pressure and kidney update 2013.Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects.Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?Management of hyperphosphataemia in chronic kidney disease-challenges and solutions Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.Novel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease.Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.Optimal use of phosphate binders in chronic kidney disease.Drug adherence in chronic kidney diseases and dialysis.Next-generation phosphate binders: focus on iron-based binders.Is there a need for new phosphate binders to treat phosphate imbalance associated with chronic kidney disease?Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies.Effects and safety of iron-based phosphate binders in dialysis patients: a systematic review and meta-analysis.Iron-based phosphate binders--a new element in management of hyperphosphatemia.Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.The challenge of controlling phosphorus in chronic kidney disease.Contemporary management of phosphorus retention in chronic kidney disease: a review.Advances in pharmacotherapy for secondary hyperparathyroidism.Novel iron-containing phosphate binders for treatment of hyperphosphatemia.Advances in pharmacotherapy for hyperphosphatemia in renal disease.Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.Treating hyperphosphatemia - current and advancing drugs.Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure.Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide.Optimal phosphate control: still an unmet need in chronic kidney disease patients Bicarbonate levels in hemodialysis patients switching from lanthanum carbonate to sucroferric oxyhydroxide

P2860

Q26764806-3B624893-934C-4FAC-8297-7CA0DBD508A7 Q27002431-7FA84099-DF6F-48BD-BE69-6C552196CC01 Q28081229-24216C12-26CC-43FA-BE52-67CC0214A9BC Q31039292-5982885E-9095-410B-993D-BB0AC9E16A47 Q33574532-767B0CB6-0D9A-4076-A30F-C0D38679956C Q33840398-A0008332-910F-4D6A-B9D9-779377229635 Q34116591-B2873470-F580-48F3-8E3E-C10529A38122 Q34413591-D6693A7F-1C16-4D55-A727-F1B1EE3531DB Q34463433-87251C3F-CE08-4500-9A7F-5DD3F886843A Q35207839-73DE5AD6-ADCF-4667-9CF6-75336369C754 Q35608435-EB80F9D9-194E-403A-A8D0-FBE3CEC512E0 Q36045060-1ED91B9B-0881-4E7E-AA68-5D818C3D1B5E Q36225208-9895F3A5-6149-4B7E-AC96-12AA0417844B Q36293813-51C27484-D91D-472C-B5CC-CEF9387A6373 Q37204047-07A1F547-DC5B-485C-9DF9-39DE1282CF94 Q38092144-E7F2FA8A-9E27-495E-B6F9-7B63CE2C6772 Q38161580-851C371B-D44D-4D3C-BF44-EC358C19D9DD Q38187107-C06DE0B2-4E69-485A-BFCF-AE6EFA41B610 Q38213502-078F0843-E092-474F-89EC-0C8B29818F42 Q38223280-061166EF-CFDE-4ECE-8222-D4BFBEFE5DC6 Q38229636-C57BDCA4-DE66-405B-9CE2-7222CEC83BCD Q38263310-DAFE962F-561B-4A00-82FC-AD565F2195B1 Q38295285-45A16D59-0169-42BE-ADCC-C48DE529892E Q38374335-7F337E2B-9467-4352-81E1-BB55F3418C46 Q38377286-62E99CB5-64CE-4BDD-A40A-BD36E928C14A Q38511621-EE9A7359-0E93-4E8E-B658-65E065B1A271 Q38544533-07C6EAB7-668E-4239-B90A-E7ED5C3CA565 Q38570622-B3131A0A-4276-4FD1-97D3-9BB10E128A90 Q38587575-7D90F836-EE60-4B1E-90A4-19B5F93AC98D Q38828902-C992982E-0373-4F1F-B63F-D49B47AD511A Q38958363-4FB6F942-D0E2-49C4-AE24-0617F7F43641 Q39440902-713E4F23-4993-46D5-9615-F62A5DB90BEB Q41007103-A7F3C4A4-854C-4FA3-8FBB-40604099364A Q46547077-FAF2D5DA-0964-4E40-A72C-2D340A1B2851 Q57217288-DFB5E1B7-232B-47A5-9BC0-A0F341078CB8 Q57479316-2C9EF420-E449-4415-BE31-D58CC30DCD34

P2860

Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients.

http://www.wikidata.org/entity/Q36583383

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Randomized clinical trial of t ...... PA21 in hemodialysis patients.

@ast

Randomized clinical trial of t ...... PA21 in hemodialysis patients.

@en

type

label

Randomized clinical trial of t ...... PA21 in hemodialysis patients.

@ast

Randomized clinical trial of t ...... PA21 in hemodialysis patients.

@en

prefLabel

Randomized clinical trial of t ...... PA21 in hemodialysis patients.

@ast

Randomized clinical trial of t ...... PA21 in hemodialysis patients.

@en

P1433

Q36583383-4641D10F-F3B7-4D03-8FE5-06DBE53DCFE2

P1476

Q36583383-A347EDAD-EC9F-4D66-B3BC-642B43154169

P2093

Q36583383-01D65F7B-878E-4417-B4A6-816CF43505A4

Q36583383-072496DE-EEC2-43AE-9306-185BD4CBA4AC

Q36583383-1B496F71-2049-43D7-A31B-92414F7CC386

Q36583383-40437D7F-A406-4426-BD23-7EEA300C5B30

Q36583383-9CA9A11F-41C2-4386-BB0F-80A2431470A9

P2860

Q36583383-053F9CD6-34CA-4945-8C71-8CEBF7FE3ACF

Q36583383-0E3A6F27-591C-4C93-AF5E-7FB41AD2B110

Q36583383-999E7050-F372-433B-9B2F-2BB987CC249B

Q36583383-B77C0252-6563-4481-BE30-E58637F6B694

Q36583383-C2F3FA6E-A7BF-471D-8F44-49FADA8A367E

Q36583383-FBA797C3-DDF8-4A4F-A853-FDFEF829B7B1

Q36583383-FD99E5EE-DD02-4584-9F52-2F6C0F790F19

P304

Q36583383-9CBE2928-EE3E-44BD-B0C8-49168958F3CC

P31

Q36583383-D804EC15-A288-4884-B2A4-FE4C53CD066A

P356

Q36583383-D1E1C66B-6086-4049-AD8B-D0448656061F

P433

Q36583383-7D29E3CF-BD57-4D24-9BC9-CAF9B0C3369A

P478

Q36583383-9F7AC62A-E962-4179-AAE2-7B16211E7038

P50

Q36583383-D7F8B0DB-D557-4141-8674-6265641E8840

P577

Q36583383-33936CF8-E88C-43BC-96BF-1771D218B44B

P698

Q36583383-D9526D32-7243-46F9-A1B3-0A06D9618F2E

P932

Q36583383-44EF022C-9CEA-4007-BAF4-3CEFFBD51799

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Randomized clinical trial of t ...... PA21 in hemodialysis patients.

@en

P2093

Edward Chong

http://www.w3.org/2001/XMLSchema#string

James A Tumlin

http://www.w3.org/2001/XMLSchema#string

Michel Chonchol

http://www.w3.org/2001/XMLSchema#string

Rudolf P Wüthrich

http://www.w3.org/2001/XMLSchema#string

Sylvain Gaillard

http://www.w3.org/2001/XMLSchema#string

P2860

Control of hyperphosphatemia among patients with ESRD.

Clinical pharmacokinetics of the phosphate binder lanthanum carbonate.

Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate.

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.

K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.

Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate.

P304

280-289

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.08230811

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23124782

http://www.w3.org/2001/XMLSchema#string

P932

3562865

http://www.w3.org/2001/XMLSchema#string